Search

Displaying results 5821 - 5830 of 7535 in total
  1. Drug

    Thalagen

    go.drugbank.com/drugs/DB17714
    Experimental

    Thalagen is a branded product developed by San Rocco Therapeutics.

  2. Drug

    Imolamine

    go.drugbank.com/drugs/DB09284
    Investigational

    It is developed under the brand name Coremax by Novartis consumer health SA.

  3. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    It is being developed by Kalypsys.

  4. Drug

    Zotiraciclib

    go.drugbank.com/drugs/DB16656
    Investigational

    Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide

  5. Drug

    Phelimin

    go.drugbank.com/drugs/DB18332
    Experimental

    Phelemin (PHE-MIP) is a methacrylic acid-based copolymer purified to bind to L-phenylalanine and L-phenylalanine-containing peptides.

  6. Drug

    Sonelokimab

    go.drugbank.com/drugs/DB18843
    Investigational

    Sonelokimab is under investigation in clinical trial NCT06411379 (Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe

  7. Drug

    Suvecaltamide

    go.drugbank.com/drugs/DB19139
    Investigational

    Suvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).

    Synonyms: 4-(1-methylethyl)-n-((1r)-1-(5-(2,2,2-trifluoroethoxy)-2-pyridinyl)ethyl)benzeneacetamide, Benzeneacetamide, 4-(1-methylethyl)-n-((1r)-1-(5-(2,2,2-trifluoroethoxy)-2-pyridinyl)ethyl)-
  8. Drug

    NP-G2-044

    go.drugbank.com/drugs/DB14995
    Investigational

    NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).

  9. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.

  10. Drug

    Cocamidopropyl betaine

    go.drugbank.com/drugs/DB11350
    Approved

    Impurities formed during the manufacturing process are thought to increase the prevalence of contact sensitization and mild skin irritations.